Semaglutide, the weight management drug sold as Ozempic and Wegovy, may reduce the risk of Alzheimer's disease by 40% to 70% ...

Find out what AI has already brought to Alzheimer's disease research and most importantly, what it can accomplish in the ...

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

If approved, the less burdensome version of Leqembi could be used to treat patients at home or in medical facilities, help ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

The Alzheimer's Association says more than 122,000 Missourians 65 years and older are battling Alzheimer's Disease, which has ...

Based on early, interim data, Lexeo is already positioning its gene therapy as a potentially safer alternative than available anti-amyloid drugs.

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

Q3 2024 CAPLYTA total prescriptions increased 38%, versus the same period in 2023 CAPLYTA 2024 net product sales guidance range raised to $665 to $685 million Following a successful pre-supplemental ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.